CSL (OTCMKTS:CSLLY) Shares Gap Up – What’s Next?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $26.0550, but opened at $28.00. CSL shares last traded at $26.19, with a volume of 5,146 shares trading hands.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on CSLLY shares. Royal Bank Of Canada lowered shares of CSL from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, February 11th. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy”.

CSL Stock Down 2.4%

The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12. The business’s 50-day simple moving average is $56.93 and its 200 day simple moving average is $61.82.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.